Seladelpar Meets Primary and Secondary Goals in the Phase 3 Response Trial.

Published Date: 14 Sep 2023

Seladelpar may help patients with PBC measure their disease activity more accurately and experience fewer symptoms overall, according to RESPONSE study findings.

Read Full News

Latest News

Pancreatic Cysts: What’s the Actual Cancer Risk?

Pancreatic cysts are common and usually considered low risk — but even those lesions signal a significantly elevated and sustained cancer risk.

UTI Treatment Shift: Is Nitrofurantoin Coming Out on Top?

A large Spanish trial reports higher cure rates with 5-day nitrofurantoin therapy than with fosfomycin or pivmecillinam in women with uncomplicated UTIs.

Takeda Engaged in Antitrust Scheme to Delay Generic Constipation Drug, US Jury Finds

A U.S. jury on Monday found Takeda Pharmaceutical liable for causing about $885 million in damages by delaying a generic version of its constipation drug Amitiza through an...

Blood Proteins Link Poor Sleep to Increased Cancer Risk

Suboptimal sleep health, reflected in low sleep proteomic scores, is consistently associated with an increased risk for cancer, particularly gastrointestinal malignancies.

Housing Instability Tied to Lower Rates of CRC Screening

Unmet health-related social needs, especially housing instability and transportation barriers, are linked to lower rates of screening for colorectal cancer among US adults.

Olanzapine Cuts Radiation-Induced Nausea

The drug, widely used for chemotherapy-related nausea, may also be highly effective for symptoms caused by abdominal-pelvic radiotherapy.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

Pancreatic cysts are common and usually considered low risk — but even those lesions signal a significantly elevated and sustained cancer risk.

A large Spanish trial reports higher cure rates with 5-day nitrofurantoin therapy than with fosfomycin or pivmecillinam in women with uncomplicated UTIs.

A U.S. jury on Monday found Takeda Pharmaceutical liable for causing about $885 million in damages by delaying a generic version of its constipation drug Amitiza through an...

Suboptimal sleep health, reflected in low sleep proteomic scores, is consistently associated with an increased risk for cancer, particularly gastrointestinal malignancies.

Unmet health-related social needs, especially housing instability and transportation barriers, are linked to lower rates of screening for colorectal cancer among US adults.

The drug, widely used for chemotherapy-related nausea, may also be highly effective for symptoms caused by abdominal-pelvic radiotherapy.

News All Time

Clinical Pearls to Advance Multidisciplinary Team-Based Care for Patients With GEP-NETs

Clinical Pearls to Advance Multidisciplinary Team-Based Care for Patients With GEP-NETs

Navigating the Future of Upper GI Cancer Treatment: Mechanisms, Personalization, and Expert Insights

Navigating the Future of Upper GI Cancer Treatment: Mechanisms, Personalization, and Expert Insights

Checkpoint, Claudin, and Beyond: Optimizing Biomarker-Driven Decisions in Advanced/Metastatic G/GEJ Cancer Care

Checkpoint, Claudin, and Beyond: Optimizing Biomarker-Driven Decisions in Advanced/Metastatic G/GEJ Cancer Care

EASL: European Association for the Study of the Liver

ACG: American College of Gastroenterology

AASLD: American Association for the Study of Liver Diseases

AASLD Video Pearls: Video Pearls from the American Association for the Study of Liver Diseases

CCC: Crohn's & Colitis Congress

Multiple Drugs Flagged for Higher C. Diff Risk

Increased risks observed for analgesics and corticosteroids, among others, in Swedish study

Dulaglutide or Tirzepatide? Worldwide Biopharma Changes

Also in TTHealthWatch: how treatments for hepatitis C have been used

Raw Dairy Farm Recalls Cheese Products as FDA Investigates E. Coli Outbreak

The company initially refused to recall the products

Is Surveillance Colonoscopy Needed for Elderly Patients With Adenomas?

Study finds deaths from other causes far surpass colorectal cancer diagnosis, death

Gaslighting in Gastro Care; Antidepressants and IBS Mortality; Diverticulitis Season

News and commentary from the world of gastroenterology and hepatology

Is Kissing for Celiacs Gluten-Free? Study Weighs In

Small trial finds little in the way of gluten transfer when celiac and non-celiac partners kiss

Strategy Reduces Inappropriate Proton Pump Inhibitor Use

Patient- and physician-facing interventions together doubled the reductions in PPI use

1.8 Billion MASLD Cases; Improving HCC Surveillance; Ultrasound for Crohn's Disease

News and commentary from the world of gastroenterology and hepatology

Recommended News For You

Studies point to redlining as a 'perfect storm' for breast cancer

improvements in the treatment of prostate cancer resistant to chemotherapy.

The Benefits of Exercise for Substance Use Disorders.

Pretreatment Liver Tests Often Overlooked in CDK4/6 Therapy

Q&A: Why adolescents and young adults with cancer are falling behind

Cancer patients with HIV have demonstrated safety with immune checkpoint inhibitors.

Gene Therapy for Rare Brain Disease Effective, but Comes With Blood Cancer Risk

Recommended Articles For You

An Overview Of Leukemia Cutis: What It Is And How To Treat It 

Understanding Leiomyoma: Causes, Symptoms, and Treatment Options 

Unlocking the Immune Arsenal: A Revolution in Cancer Treatment 

Unlocking the Potential of Ferrotonia: A New Way to Harness Magnetic Energy 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods

1.

How Digital Innovation and AI-Powered Case Studies are Revolutionizing Oncology Education?

2.

Advancements in Survival Mechanisms and Prognostic Determinants in Acute Myeloid Leukemia

3.

Unveiling the Hidden Mechanisms of Hemolytic Reactions

4.

Blastic Plasmacytoid Dendritic Cell Neoplasm and the Dawn of AI-powered Diagnostics

5.

Understanding Epoetin and Its Role in Treating Chronic Kidney Disease 

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Current Scenario of Cancer- Q&A Session to Close the Gap

2.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V

3.

Updates on Standard V/S High Risk Myeloma Treatment- The Next Part

4.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I

5.

Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot